Establishment Labs Holdings INC 8-K filings

Establishment Labs Holdings Inc. announced robust second quarter 2026 financial results, featuring a 31.7% year-over-year revenue increase and a raised full-year revenue outlook.

Establishment Labs Holdings Inc. announced the appointment of Taylor Harris to its Board of Directors, effective immediately, bringing extensive experience in healthcare finance and leadership.

Establishment Labs Holdings Inc. shareholders re-elected all director nominees and ratified the appointment of its independent auditor at the 2026 Annual Meeting.

Establishment Labs Holdings Inc. announced first quarter 2026 financial results, showcasing significant revenue growth, improved gross margins, and a narrowed operating loss, leading to raised annual guidance.

Establishment Labs Holdings Inc. has entered into a new $300 million credit agreement to refinance existing debt and support general corporate operations.

Establishment Labs Holdings Inc. announced robust fourth-quarter and full-year 2025 financial results, alongside optimistic revenue guidance for 2026 and 2027.

Establishment Labs Holdings Inc. filed an 8-K to furnish presentation materials from its J.P. Morgan Healthcare Conference appearance.

Establishment Labs Holdings Inc. announced preliminary unaudited financial results for Q4 and fiscal year 2025, projecting record quarterly revenue and 27% annual growth.

Establishment Labs Holdings Inc. reported robust third-quarter 2025 financial results, including a 33.8% revenue increase and positive Adjusted EBITDA, leading to an upward revision of its full-year 2025 revenue guidance.

Establishment Labs Holdings Inc. amended its credit agreement to access $25 million in Tranche D Term Loans, waiving a prior revenue milestone, and increased its minimum liquidity requirement to $30 million.

Establishment Labs reported strong Q2 2025 revenue growth and improved gross margin, leading to an upward revision of its full-year 2025 revenue guidance.

Establishment Labs Holdings Inc. announced robust US sales for its Motiva implants, exceeding 1,000 offering surgeons, and outlined plans for a Q4 2025 US FDA reconstruction filing and a 2026 US launch for Preserv, alongside positive financial guidance for 2025.

Establishment Labs Holdings Inc. announced that its shareholders re-elected all five director nominees, approved executive officer compensation on an advisory basis, and ratified the appointment of CBIZ, CPAs P.C. as its independent registered public accounting firm at the Annual Meeting held on May 23, 2025.

Establishment Labs Holdings Inc. has appointed CBIZ CPAs P.C. as its new independent registered public accounting firm following Marcum LLP's acquisition by CBIZ.

Establishment Labs announced its Q1 2025 financial results, reporting worldwide revenue of $41.4 million and maintaining its 2025 revenue guidance of $205 million to $210 million.

Establishment Labs Holdings Inc. appoints Fillipo 'Peter' Caldini as its permanent Chief Executive Officer, effective May 7, 2025, after he served as interim CEO.

Establishment Labs expects preliminary Q1 2025 revenue of approximately $41.4 million and will host an investor day on June 12, 2025.

Establishment Labs announces its Q4 and full year 2024 financial results, highlighting U.S. market entry and reaffirming its 2025 revenue guidance.

Establishment Labs projects revenue between $205 million and $210 million for 2025, with positive adjusted EBITDA expected in 2025 and positive cash flow in 2026.

Establishment Labs announces the retirement of CEO Juan Jos Chacn-Quirs, effective March 1, 2025, with President Peter Caldini stepping in as Interim CEO, and reports preliminary unaudited revenue for Q4 and full year 2024.

Establishment Labs Holdings Inc. has entered into a securities purchase agreement for a direct offering of common shares and pre-funded warrants, and amended its credit agreement to extend the commitment termination date and modify loan availability milestones.

Establishment Labs has announced a $50 million registered direct offering of common shares and pre-funded warrants, along with updated revenue expectations for 2024 and 2025.

Establishment Labs announced its third quarter 2024 financial results, highlighted by a successful US launch of Motiva implants and an updated revenue guidance for the year.

Establishment Labs has received FDA approval for its Motiva SmoothSilk Ergonomix and Round breast implants, signaling a significant advancement in breast augmentation technology in the United States.

Establishment Labs Holdings Inc. has appointed Fillipo 'Peter' Caldini as its new President, effective immediately, with a compensation package including a $415,000 base salary, bonus potential, and significant equity grants.

Establishment Labs announced its second quarter 2024 financial results, showing revenue of $44.1 million and a reduced operating loss, while awaiting FDA approval for its Motiva Implants.

Establishment Labs announced that the FDA will begin its preapproval inspection of the company's manufacturing facility for Motiva Implants on July 22, 2024.

Establishment Labs has received a letter from the FDA stating its premarket approval application for Motiva Implants is approvable, contingent on a successful facility inspection.

Establishment Labs Holdings Inc. held its 2024 Annual Meeting on May 24, 2024, where shareholders voted on the election of directors, executive compensation, and the ratification of the company's accounting firm.

Establishment Labs announced a decrease in first quarter revenue but also a significant reduction in operating and adjusted EBITDA losses, alongside progress on key product approvals.